An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors
A study for patients with solid tumors using study drug ASP5878
Sponsor: Astellas
Enrolling: Male and Female Patients
IRB Number: AAAP3615
U.S. Govt. ID: NCT02038673
Contact: Emerson Lim: 212-305-1820 / el2342@columbia.edu
Additional Study Information: The purpose of this research study is to confirm the safety of ASP5878. It is also intended to assess how the body reacts to ASP5878 after administration, how ASP5878 functions in the body, and the antitumor effect of the ASP5878. Participants in this study will have been diagnosed with urothelial carcinoma, hepatocellular carcinoma, or squamous cell lung carcinoma. Additionally, participants must test positive for a FGF/FGRF mutation/overexpression.
This study is closed
Investigator
Emerson Lim, MD
Do You Qualify?
Do you have a confirmed diagnosis of urothelial carcinoma, hepatocellular carcinoma or squamous cell lung carcinoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Emerson Lim
el2342@columbia.edu
212-305-1820
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE